Australia

Admedus’ 3D single-piece aortic valve has potential to transform heart surgery

Admedus Ltd (ASX:AHZ) has entered human trials with the first Australian-developed 3D single-piece aortic valve, DurAVR™, which has the potential to transform heart surgery.

The Brisbane-based company is focused on bringing DurAVR™ to market, building on the companys cardiovascular patches using its ADAPT® tissue technology.

This tissue technology, invented by Perth professor Leon Neethling, has been taken from discovery to global commercialisation and has proven to be the only tissue to last beyond 10 years in the human body.

It is this tissue that forms the basis of the new valve, which is attracting the attention of leading global doctors and potential partners.

Admedus is partnered with cardiac specialists from Harvard, Mayo, Columbia University, and the Cleveland Clinic (the largest cardiac centre in the world) to develop this valve.

First in-human trial


In a major step forward for the company, DurAVR™ was successfully implanted into the first patient at the University Hospitals Leuven in Belgium earlier this month.

Professor Bart Meuris MD, PhD, Chief of Cardiovascular Surgery at the University Hospitals, Leuven, Belgium conducted the cardiac heart valve surgery.

Fifteen patients will be enrolled in the first-in-human study and followed up for six months after receiving implantation of the ADAPT® single-piece 3D aortic valve.

Performing better than expected


Admedus chief executive officer Wayne Paterson told Proactive that the single-piece valve design was performing far better than anything else out there.

“This is really exciting and a lot of credit to not only the professor who performed the study but to the patient who decided to undergo that procedure.

“The valve is performing the way weve seen it on the bench and animal studies are duplicating that data.

“This was a big step for the hospital to be able to do that.”

Event-free surgery


Paterson added the patient had recovered well enough to be discharged within one week of receiving an event-free surgery, with normal gradients upon dismissal.

In heart surgery, one of the biggest issues facing patients – and surgeons – is finding a replacement valve that will last the life of tRead More – Source